

Consolidated Financial Results for the First Quarter of the Fiscal Year Ending February 28, 2026 [Japanese GAAP]

July 10 2025

Company name: Hisamitsu Pharmaceutical Co., Inc.
 Stock exchange listing: Tokyo, Nagoya, Fukuoka
 Securities code: 4530
 URL: <https://global.hisamitsu/>
 Representative: NAKATOMI Kazuhide, President & CEO
 Contact: ISOBE Yuichi, Director Executive Officer Head of Corporate Strategy Planning Division
 TEL: +81-3-5293-1704
 Scheduled date of dividend payment: —
 Preparation of supplementary materials for financial results: Yes
 Holding of financial results meeting: Yes (for institutional investors and analysts, etc.)

(Amounts are rounded down to the nearest millions of yen)

1. Consolidated Financial Results for the First Quarter of the Fiscal Year Ending February 28, 2026

(March 1, 2025 to May 31, 2025)

(1) Consolidated Operating Results

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended May 31, 2025	34,665	(3.2)	3,364	(18.9)	3,780	(32.0)	2,564	(46.4)
Three months ended May 31, 2024	35,810	11.6	4,149	(4.9)	5,562	(2.7)	4,788	18.2

(Note) Comprehensive income: Three months ended May 31, 2025 (3,247) millions of yen [—%]
 Three months ended May 31, 2024 12,025 millions of yen [85.0%]

	Profit per share	Diluted profit per share
	yen	yen
Three months ended May 31, 2025	35.14	35.10
Three months ended May 31, 2024	63.89	63.82

(2) Consolidated Financial Position

	Total assets	Net assets	Shareholders' equity ratio
	Millions of yen	Millions of yen	%
As of May 31, 2025	334,934	272,933	80.6
As of Feb. 28, 2025	343,068	279,407	80.6

(Reference) Shareholders' equity: As of May 31, 2025 270,065 millions of yen
 As of Feb. 28, 2025 276,417 millions of yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Fouth quarter	Total
	yen	yen	yen	yen	yen
Year ended Feb. 28, 2025	—	45.00	—	45.00	90.00
Year ending Feb. 28, 2026	—				
Year ending Feb. 28, 2026 (Forecast)		60.00	—	60.00	120.00

(Note) 1. Revisions to the most recently announced dividends forecast: No

2. Breakdown of annual dividend forecast for the fiscal year 2025

Ordinary dividend 86.00 yen

Commemorative dividend 4.00 yen (A commemorative dividend for the 90th anniversary of the launch of SALONPAS®)

Breakdown of annual dividend forecast for the fiscal year 2026

Ordinary dividend 90.00 yen

Commemorative dividend 30.00 yen (A commemorative dividend for the 30th anniversary of the launch of MOHRUS® Tapes)

3. Consolidated Earnings Forecast for the Fiscal Year Ending February 28, 2026 (March 1, 2025 to February 28, 2026)

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Profit per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
Full year	165,000	5.8	20,000	5.8	24,300	1.2	22,000	1.1	301.45

(Note) Revisions to the most recently announced consolidated forecast: No

*Notes

- (1) Changes in significant subsidiaries during the period : None
(Changes in specified subsidiaries resulting in changes in scope of consolidation)
- (2) Application of special accounting methods for preparation of quarterly consolidated financial statements : Yes
- (3) Changes in accounting policies, changes in accounting estimates, and restatement
- 1) Changes in accounting policies due to revision of accounting standards : Yes
 - 2) Changes in accounting policies other than 1) above : None
 - 3) Changes in accounting estimates : None
 - 4) Restatement : None
- (4) The number of shares outstanding (common stock)
- 1) Total number of shares outstanding at the end of the period (including treasury stock)
 - As of May 31, 2025 85,164,895 shares
 - As of Feb. 28, 2025 85,164,895 shares
 - 2) Total number of treasury stock at the end of the period
 - As of May 31, 2025 12,157,227 shares
 - As of Feb. 28, 2025 12,202,127 shares
 - 3) Average number of shares outstanding during the period
 - Three months ended May 31, 2025 72,981,068 shares
 - Three months ended May 31, 2024 74,943,114 shares

(Note) The number of treasury stock at the end of the period includes the Company's shares (364,700 shares as of May 31, 2025. 379,600 shares as of Feb.28, 2025.) held by the "HISAMITSU PHARMACEUTICAL Employee Stockholding Partnership Plan Trust Account". In addition, the Company's shares held by the "HISAMITSU PHARMACEUTICAL Employee Stockholding Partnership Plan Trust Account" are included in the treasury stock deduction in the calculation of the average number of shares during the period (371,300 shares for the three months ended May 31, 2025. —shares for the three months ended May 31, 2024).

*Review of the attached quarterly consolidated financial statements by a certified public accountant or an independent auditor: None

*Explanation for appropriate use of financial forecasts and other special notes

Among this document, the forecasts based on the plan may changes due to uncertain factors. Therefore, the actual operating results may differ from the company's view.

Financial settlement briefings for institutional investors and analysts will be held on July 10, 2025. Presentation materials of financial results will be posted promptly on the company's website after the financial settlement briefings.

Quarterly Consolidated Financial Statements
(1) Quarterly Consolidated Balance sheets

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 28, 2025)	Current First Quarter (As of May 31, 2025)
Assets		
Current assets		
Cash and deposits	114,518	104,107
Notes and accounts receivable - trade, and contract assets	47,223	47,438
Securities	14,598	14,020
Merchandise and finished goods	12,044	14,136
Work in process	794	947
Raw materials and supplies	9,553	10,046
Other	5,400	7,092
Allowance for doubtful accounts	(344)	(349)
Total current assets	203,780	197,439
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	29,045	28,151
Other, net	30,854	30,315
Total property, plant and equipment	59,899	58,467
Intangible assets		
Sales rights	300	288
Goodwill	1,294	1,256
Other	4,380	4,317
Total intangible assets	5,974	5,862
Investments and other assets		
Investment securities	60,222	60,168
Other	13,389	13,208
Allowance for doubtful accounts	(207)	(207)
Total investments and other assets	73,405	73,165
Total non-current assets	139,280	137,495
Total assets	343,068	334,934

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 28, 2025)	Current First Quarter (As of May 31, 2025)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	9,910	9,523
Electronically recorded obligations - operating	4,205	6,263
Short-term loans payable	1,065	963
Income taxes payable	3,627	1,282
Provision for bonuses	2,213	510
Other	26,203	27,439
Total current liabilities	47,226	45,983
Non-current liabilities		
Long-term loans payable	1,694	1,683
Net defined benefit liability	7,819	7,775
Other	6,920	6,559
Total non-current liabilities	16,434	16,018
Total liabilities	63,661	62,001
Net assets		
Shareholders' equity		
Capital stock	8,473	8,473
Capital surplus	2,361	2,359
Retained earnings	257,881	257,144
Treasury shares	(47,550)	(47,368)
Total shareholders' equity	221,166	220,608
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	18,485	18,647
Revaluation reserve for land	3,337	3,337
Foreign currency translation adjustment	31,334	25,489
Remeasurements of defined benefit plans	2,093	1,982
Total accumulated other comprehensive income	55,250	49,456
Share acquisition rights	408	310
Non-controlling interests	2,581	2,557
Total net assets	279,407	272,933
Total liabilities and net assets	343,068	334,934

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2024 – May 31, 2024)	Current Fiscal Year (Mar. 1, 2025 – May 31, 2025)
Net sales	35,810	34,665
Cost of sales	15,005	13,379
Gross profit	20,804	21,285
Selling, general and administrative expenses	16,655	17,920
Operating profit	4,149	3,364
Non-operating income		
Interest income	728	498
Dividend income	119	101
Foreign exchange gains	381	—
Share of profit of entities accounted for using equity method	—	21
Other	333	169
Total non-operating income	1,562	790
Non-operating expenses		
Interest expenses	4	2
Share of loss of entities accounted for using equity method	114	—
Foreign exchange losses	—	342
Other	31	30
Total non-operating expenses	149	375
Ordinary profit	5,562	3,780
Extraordinary income		
Gain on disposal of non-current assets	2	—
Gain on sale of investment securities	1,352	18
Total extraordinary income	1,354	18
Extraordinary losses		
Loss on disposal of non-current assets	0	6
Total extraordinary losses	0	6
Profit before income taxes	6,915	3,791
Income taxes	1,944	1,154
Profit	4,971	2,637
Profit attributable to non-controlling interests	182	73
Profit attributable to owners of parent	4,788	2,564

Quarterly Consolidated Statements of comprehensive income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2024 – May 31, 2024)	Current Fiscal Year (Mar. 1, 2025 – May 31, 2025)
Profit	4,971	2,637
Other comprehensive income		
Valuation difference on available-for-sale securities	1,209	184
Foreign currency translation adjustment	5,919	(5,936)
Remeasurements of defined benefit plans, net of tax	(78)	(132)
Share of other comprehensive income of entities accounted for using equity method	3	(0)
Total other comprehensive income	7,054	(5,884)
Comprehensive income	12,025	(3,247)
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	11,815	(3,229)
Comprehensive income attributable to non-controlling interests	209	(17)



Promoting“TE-A-TE” Culture Worldwide

「手当て」の文化を、世界へ。

